

Note from the Sponsor: rationale to request an extension to submit paediatric clinical trial results

Sponsor name:	Janssen-Cilag International NV
EudraCT number:	2020-002873-88
Protocol number:	MGT-RPGR-021
Clinical trial title:	Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated with Variants in the RPGR gene
Objective scientific reason to request extension of the 6-month due date to submit result-related information for a paediatric trial:	The company requested to defer submission of the MGT-RPGR-021 trial results from 6 months to 12 months after study completion, to preserve the scientific integrity of the Week 52 data of the ongoing MGT-RPGR-022 follow-up trial.